PainReform Stock (NASDAQ:PRFX)
Previous Close
$1.40
52W Range
$0.43 - $16.63
50D Avg
$1.86
200D Avg
$2.19
Market Cap
$2.78M
Avg Vol (3M)
$208.79K
Beta
0.62
Div Yield
-
PRFX Company Profile
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.